✦ LIBER ✦

Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder

✍ Scribed by Robert A. Lasser; Cynthia A. Bossie; Young Zhu; Georges Gharabawi; Mariëlle Eerdekens; Michael Davidson

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 93 KB
Volume: 19
Category: Article
ISSN: 0885-6230
DOI: 10.1002/gps.1184

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long‐acting risperidone, the first long‐acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery.

Objective

To assess the efficacy and safety of long‐acting injectable risperidone in elderly patients with psychotic disorders.

Methods

This is a subanalysis of 57 patients aged ≥65 years enrolled in an open‐label study of long‐acting risperidone that included 725 symptomatically stable patients with schizophrenia or schizoaffective disorder. Patients were assigned to receive 25, 50, or 75 mg of long‐acting risperidone every 2 weeks for up to 50 weeks.

Results

Fifty‐seven elderly patients (mean ± SE age, 70.9 ± 0.7 years) were enrolled. Mean Positive and Negative Syndrome Scale (PANSS) total scores improved significantly throughout the study and at endpoint (p < 0.001). The PANSS factor scores (positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression) also significantly improved (p < 0.01). Clinical improvement (≥20% reduction in PANSS total scores) was achieved by 49% of these stable patients, and 55% improved on the Clinical Global Impressions scale. Severity of movement disorders (Extrapyramidal Symptom Rating Scale scores) was reduced significantly. Adverse events reported in >10% of patients were insomnia (14%), constipation (12%), and bronchitis (12%).

Conclusions

Long‐acting risperidone was associated with significant symptom improvements in stable elderly patients with schizophrenia or schizoaffective disorder. Treatment was well tolerated. Copyright © 2004 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Long-term safety and efficacy of long-ac

Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients

✍ Werner Kissling; Per Glue; Rossella Medori; Steve Simpson 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

## Abstract This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot a

Comparative effects of risperidone and o

Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder

✍ Philip D. Harvey; Judy A. Napolitano; Lian Mao; Georges Gharabawi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

## Abstract ## Objective To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder. ## Method One hundred seventy‐six elderly inpatients and outpatients with schizophrenia or schizoaffective disorder were enro

Safety and efficacy of long-acting injec

Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients

✍ Swapna Verma; Mythily Subramaniam; Edimansyah Abdin; Kang Sim; Alex Su; Nelson L 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Abstract The study aimed to evaluate the efficacy of long‐acting injectable risperidone (LAR) in Asian patients with schizophrenia spectrum disorders. Twenty‐five patients enrolled in this 6‐month open labelled study. They were switched from their current antipsychotic to LAR without a prior or

Remission in schizophrenia: one-year Ita

Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder

✍ Alessandro Rossi; Anna Bagalà; Vincenzo Del Curatolo; Francesco Scapati; Micaela 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

## Abstract ## Objectives To evaluate the maintenance of efficacy of risperidone long‐acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders. The prevalence of patients who met standardized remission criteria will be also evaluated as well as the predictors fac

Long-term treatment with long-acting ris

Long-term treatment with long-acting risperidone in Korean patients with schizophrenia

✍ Moon-Soo Lee; Young-Hoon Ko; Sang-Hoon Lee; Yong-Jin Seo; Seung-Hyun Kim; Sook-H 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract ## Objectives We evaluated the efficacy and safety of long‐acting risperidone for 48‐week period in Korean patients. ## Methods This was a non‐randomized, open‐label, single‐centered, 48‐week study. Each of the participants visited the hospital every 2 weeks, and injections were give

Switching stable patients with schizophr

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety

✍ Chris Hawley; Martin Turner; Muhammud A Latif; Vivienne Curtis; Packeruther T Sa 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 1 views

## Abstract ## Objective An international, non‐randomised study evaluated efficacy and safety of risperidone long‐acting injectable (RLAI) compared to previous treatment. To investigate generisability of the European data set to the UK subset safety and switching data are reported here. ## Method